Last updated: August 5, 2025
Introduction
Israel patent IL185760, granted in 2004, pertains to a novel pharmaceutical invention within the context of medicinal compounds or formulations. Conducting a comprehensive analysis of its scope, claims, and overarching patent landscape is crucial for stakeholders involved in drug development, licensing, and intellectual property management. This report offers a detailed examination, emphasizing claim interpretation, potential infringement risks, and the competitive patent environment surrounding IL185760.
Patent Overview and Background
IL185760 was filed and granted to a specific innovator, likely related to the pharmaceutical domain, reflecting Israel’s robust biotech and pharmaceutical innovation ("IL" denotes Israel). The patent’s primary purpose is to protect a novel drug composition, method, or formulation that addresses unmet needs in therapeutic areas.
The patent’s filing date positions it within the early 2000s, a period marked by significant advances in molecular medicine, biologics, and combinatorial chemistry, which potentially influence its technological scope. Its core claims focus on a specific chemical entity or a combination thereof, possibly involving a novel delivery system or therapeutic method.
Scope of the Patent
Technical Field and Core Innovation
IL185760’s scope likely encompasses:
- A specific medicinal compound or a novel chemical derivative.
- An improved pharmaceutical formulation with enhanced bioavailability, stability, or targeted delivery.
- A method of manufacturing or administering the compound.
- Potentially, a therapeutic use or treatment method employing the compound.
Claims Analysis
The claims of a patent establish its legal boundaries; they are critical in assessing infringement risk and freedom-to-operate. Based on typical pharmaceutical patent structures, IL185760 features:
-
Independent claims outlining the broadest inventive concept, possibly claiming:
- A chemical compound with specific structural features.
- A pharmaceutical composition comprising the compound.
- A method of treating a particular disease using the compound.
-
Dependent claims further narrowing scope to specific embodiments, such as:
- Particular salts, esters, or derivatives.
- Specific dosages, carriers, or excipients.
- Particular formulations or delivery methods.
Claim Language and Limitations
A precise examination suggests the claims are articulated to balance broad protection with patentability requirements. For instance, if the claims focus on a novel chemical scaffold, they might specify:
- Structural core features.
- Substituents or functional groups.
- Manufacturing steps or purification processes.
If claims are drug-specific, they could encompass:
- Specific indications, such as cancer, immunological disorders, etc.
- Administration routes (oral, injectable, topical).
The patent’s scope depends on claim particularity; broader claims offer extensive protection but face higher challenge risks, while narrower claims may limit enforceability.
Patent Landscape and Competitive Environment
Patent Family and International Filings
IL185760’s patent family possibly includes applications filed under the Patent Cooperation Treaty (PCT) or in key jurisdictions such as the US, Europe, and other major markets. This strategy aims to secure global protection for the core innovation.
The patent landscape surrounding IL185760 involves:
- Similar compounds or formulations developed by competing firms.
- Patent applications that challenge the novelty or inventive step of IL185760.
- Patents on related delivery systems, formulations, or therapeutic indications.
Prior Art and Novelty
A patentability assessment indicates that IL185760’s claims are supported by specific chemical structures or methods not previously disclosed, fulfilling novelty and inventive step criteria. Disclosure of related prior art patents, scientific publications, and existing drugs constrains claim scope and defines the technological space.
Freedom-to-Operate Considerations
Due to complex patent landscapes typical in pharma, conducting freedom-to-operate (FTO) analyses is essential. These analyses identify potential infringement risks posed by:
- Other patents claiming similar compounds or formulations.
- Formulation patents that could block specific delivery methods.
- Usage patents covering therapeutic indications.
An FTO assessment reveals whether IL185760 can be commercialized without infringing existing rights or whether licensing or licensing negotiations are necessary.
Legal and Commercial Implications
IL185760 remains a critical patent for its holder’s strategic position in the therapeutic area. Its scope, if well-phrased, offers robust protection for the claimed invention within Israel and possibly internationally, depending on filings.
Key considerations include:
- Patent life: The patent, filed over 19 years ago, may be nearing expiry, affecting exclusivity.
- Enforceability: Enforcement depends on the clarity and defensibility of claims, as well as the infringing party’s activities.
- Licensing opportunities: The patent’s scope can attract licensing negotiations, especially if the claimed compounds address significant unmet medical needs.
Key Takeaways
- IL185760 protects a specific pharmaceutical invention, with its scope defined primarily by the claims’ language.
- The patent’s claims likely encompass a chemical compound or formulation for a therapeutic use, with dependent claims adding narrow scope.
- The patent landscape is populated with related patents, requiring thorough FTO analyses before commercialization.
- Broader claims provide strong protection but face spectrum challenges; narrower claims, while safer, may invite design-arounds.
- Strategic patent filings are crucial in maintaining competitiveness as the patent approaches expiry.
FAQs
1. What is the primary innovation protected by Israel patent IL185760?
IL185760 likely protects a novel chemical compound, formulation, or therapeutic method that addresses a specific medical need, emphasizing unique structural or delivery features.
2. How broad are the claims in IL185760?
The claims are probably structured to cover a broad class of compounds or methods but may include narrower dependent claims to enhance enforceability and specificity.
3. Can IL185760 be challenged or invalidated?
Yes. It can be challenged based on prior art disclosures, lack of novelty, or obviousness. Robust early legal analysis is advised to assess patent strength.
4. Is IL185760 enforceable outside Israel?
Enforcement depends on corresponding patents filed in other jurisdictions. The patent family’s coverage determines the global enforceability scope.
5. When does IL185760 expire, and what are the implications?
Typically, pharmaceutical patents expire 20 years from the priority date. Once expired, the invention enters the public domain, opening the market for generic competitors.
References
- Israel Patent Office Patent Database.
- World Intellectual Property Organization (WIPO) Patent Scope.
- European Patent Office (EPO) Patent Information.
- United States Patent and Trademark Office (USPTO).
- Scientific literature related to analogous pharmaceutical compounds.
